Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.

ABSTRACT:

Aims/introduction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were reported to increase hemoglobin levels in short-term clinical trials. Whether it is also true in real clinical practice is unknown.

Materials and methods

This is a retrospective cohort study. Inclusion criterion was diabetes patients who visited our outpatient clinic from January 2019 to August 2020. Exposure of interest was the use of SGLT2i. Outcomes were hemoglobin levels. For the cross-sectional analyses, non-linear regression models were fitted with restricted cubic splines to investigate the association between hemoglobin levels and estimated glomerular filtration rate (eGFR) for users and non-users of SGLT2i. For the case-control study, cases (anemia defined as hemoglobin <120 g/L for men, <110 

SUBMITTER: Murashima M 

PROVIDER: S-EPMC9017638 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature